Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 168

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 168
---
, officer or controlling person in connection with the securities being registered,  
 the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate 
 jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be          
 governed by the final adjudication of such issue.                                                                                                |

| II-3 |

| (c) | The undersigned registrant hereby undertakes that: |

| (1) | For purposes of determining any liability under the Securities Act of 1933, the information omitted from                                   
 the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed 
 by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration    
 statement as of the time it was declared effective.                                                                                        |

| (2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment                          
 that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and 
 the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.                            |

| II-4 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has
duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cardiff, Wales, on
this 17 day of November, 2025.

| BIODEXA PHARMACEUTICALS PLC |                         |
| By:                         | /s/ Stephen Stamp       |
|                             | Stephen Stamp           |
|                             | Chief Executive Officer |

KNOW ALL BY THESE PRESENTS,
that each person whose signature appears below constitutes and appoints Stephen Stamp and Stephen Parker, each in their individual capacity,
as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in
his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective
am